Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study

BACKGROUND: Major depressive disorder (MDD) is a global health concern. This study examined the efficacy, safety and tolerability of an extended-release (ER) formulation of levomilnacipran, an antidepressant approved for the treatment of MDD in adults. METHODS: This 10-week (1-week placebo run-in pe...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Bakish, David, Bose, Anjana, Gommoll, Carl, Chen, Changzheng, Nunez, Rene, Greenberg, William M., Liebowitz, Michael, Khan, Arif
Format: Artigo
Langue:Inglês
Publié: Canadian Medical Association 2014
Sujets:
Research Papers
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3868664/
https://ncbi.nlm.nih.gov/pubmed/24144196
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1503/jpn.130040
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires